Clinical Trial Update: GM-CSF in Patients With Pulmonary Alveolar Proteinosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating GM-CSF in patients with Pulmonary Alveolar Proteinosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Alveolar Proteinosis

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Pulmonary Alveolar Proteinosis | Phase 2 | Status: TERMINATED